Why Side Effects Happen

GLP-1 receptor agonists slow gastric emptying, change hunger and fullness signals in the brain, and affect digestion, appetite, and blood sugar regulation. These mechanisms produce the weight loss effect, but they also cause the gastrointestinal symptoms that many patients experience during the first weeks of treatment.

Key Takeaways
  • Side effects are dose-dependent and time-limited, with only 4.5% of semaglutide patients in the STEP 1 trial discontinuing due to gastrointestinal events.
  • Nausea is most common during the first few weeks of treatment and after dose increases. Symptoms often improve as the body adapts.
  • Constipation affects 10-24% of patients because food moves more slowly through the digestive system; daily walking and increased water intake help manage it.
  • Body composition data from STEP 1 showed both fat mass and lean mass decreased during weight loss; because lean mass includes muscle and other tissues, protein intake and resistance training help preserve muscle.

The critical insight from clinical trial data is that side effects are dose-dependent and time-limited. Most patients who tolerate the titration period go on to use the medication long-term with minimal or no ongoing symptoms [1].

Free checklist

Rough first few weeks? Most of it is manageable.

Get our free Side-Effect Relief Checklist: what helps with nausea, constipation, and fatigue, week by week. One email, instant download.

Week 1-2: First Dose

All GLP-1 treatments begin at the lowest available dose. For semaglutide (Wegovy), that is 0.25 mg weekly. For tirzepatide (Zepbound), it is 2.5 mg weekly.

Common experiences at starting dose:

  • Mild nausea, most often experienced in the hours following the injection (timing varies by patient)
  • Reduced appetite, which is an intended effect of the medication. However, very low food intake should be discussed with a provider.
  • Mild headache in some patients
  • Occasional fatigue

How common: In the STEP 1 trial, 44% of semaglutide patients reported nausea at some point during treatment, but only 4.5% discontinued due to gastrointestinal events [1]. At the starting dose, rates are substantially lower.

Management:

  • Some patients prefer taking the injection in the evening, but timing should be individualized based on side effects and daily routine
  • Eat smaller portions throughout the day rather than large meals
  • Avoid greasy, fried, or very sweet foods, which can worsen nausea
  • Stay hydrated with water and clear fluids

Week 3-4: Adaptation

Your body begins adjusting to the medication at the starting dose. Most patients report that initial nausea improves or resolves by the end of week 4.

New symptoms that may emerge:

  • Constipation (affects 10-24% of patients [2]) because food moves more slowly through the digestive system
  • Bloating or early fullness after small meals
  • Mild acid reflux in some patients

Management:

  • Increase fiber intake gradually through fruits, vegetables, and whole grains
  • Aim to stay well hydrated; fluid needs vary, but many adults benefit from drinking water regularly throughout the day
  • Consider a stool softener if constipation persists (consult your provider)
  • Walking 20-30 minutes daily helps with both constipation and overall tolerability

Week 5-8: First Dose Escalation

The titration schedule calls for a dose increase, typically at week 4 or 5. This is when many patients experience a temporary return of nausea.

What to expect:

  • Nausea recurrence that is typically milder than the initial onset and resolves faster
  • Possible diarrhea or loose stools for several days after the increase
  • Noticeable decrease in appetite at the higher dose
  • Some patients begin to notice more apparent weight loss by this stage, though the amount varies widely

Key guidance: If side effects at the current dose have not resolved, do not increase. Talk to your provider about extending the time at your current dose before escalating. The titration schedule in the prescribing information is a guide, not a rigid requirement [3].

Month 2-3: Building Toward Target Dose

Most patients go through 3-5 dose increases over 16-20 weeks to reach their target dose. Each dose increase may temporarily bring back gastrointestinal symptoms, but the pattern is consistent: 3-7 days of mild symptoms followed by adaptation.

Typical experience by month 3:

  • GI symptoms are absent or mild for most patients
  • Progressive weight loss is common at this stage, but the amount varies based on medication, dose, adherence, and individual response
  • Eating patterns have stabilized around smaller portions
  • Energy levels may improve for some patients, while others may notice fatigue if food or fluid intake is too low

Less common symptoms that may appear:

  • Acid reflux or GERD symptoms (occurs in approximately 5-10% of patients)
  • Changes in taste preferences
  • Mild dizziness, usually related to reduced caloric intake rather than the medication directly

Month 3-6: Target Dose Maintenance

Patients who reach their target dose and tolerate it well often see the most noticeable weight loss during this period, though individual results vary.

Side effects at this stage are generally minimal. The two concerns that may emerge are related to the weight loss itself, not the medication:

Hair thinning (telogen effluvium): Rapid weight loss can trigger temporary hair shedding, typically appearing 3-6 months after significant weight loss begins. This is a known response to caloric restriction, not a direct drug effect, and hair regrowth occurs after weight stabilizes. Adequate protein intake should be individualized based on body size, kidney function, and clinical goals; many patients benefit from prioritizing protein with each meal. If hair shedding occurs, discuss nutrition, iron/ferritin, thyroid status, and other possible contributors with your provider before starting supplements. Biotin should be used cautiously because it can interfere with certain lab tests, including thyroid and cardiac biomarkers.

Body composition changes: GLP-1 medications reduce appetite broadly, which can lead to inadequate protein intake. Body composition analyses from the STEP 1 trial showed that both fat mass and lean mass decreased during weight loss [1]. Because lean mass includes muscle and other tissues, patients should prioritize protein intake and resistance training to help preserve muscle.

Rare but Serious Side Effects

These affect a small percentage of patients but require immediate medical attention:

Pancreatitis: Pancreatitis is uncommon in clinical trials, but it is a serious potential adverse event. Seek urgent medical care for severe, persistent abdominal pain, especially if it radiates to the back or is accompanied by vomiting [2].

Gallbladder disease: Rapid weight loss increases gallstone risk regardless of how the weight is lost. Symptoms include pain in the upper right abdomen after meals, especially fatty meals. Contact your provider.

Severe allergic reaction: Facial swelling, difficulty breathing, or widespread rash. Extremely rare. Seek emergency care.

Thyroid concerns: GLP-1 medications carry a boxed warning based on thyroid C-cell tumors observed in rodent studies [3]. Report any new neck lump, persistent hoarseness, or difficulty swallowing to your provider. No causal link has been established in humans.

⚠️Important

Seek urgent or emergency medical care for severe abdominal pain, persistent vomiting, signs of dehydration, difficulty breathing, facial or throat swelling, or symptoms of a severe allergic reaction. These can indicate pancreatitis, severe dehydration, or anaphylaxis and require immediate medical evaluation.

When to Contact Your Provider

  • Nausea or vomiting that prevents eating or drinking for more than 24 hours
  • Severe or worsening abdominal pain
  • Signs of dehydration (dark urine, dizziness, rapid heartbeat)
  • Symptoms that worsen rather than improve with each passing week
  • Any new or unexpected symptom

Find a GLP-1 provider near you who offers ongoing monitoring and side effect management as part of their treatment program.

Ready to start your weight loss journey? Find a GLP-1 clinic near you and connect with a qualified provider today.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting any medication.

Find a GLP-1 Clinic Near You

If you'd rather see a provider in person, browse our directory of GLP-1 clinics near you — over 9,700 verified clinics across all 50 states, searchable by city, state, or ZIP code. You can also find a GLP-1 doctor near you by state or take our 60-second provider quiz for personalized matches.

Sources

  1. Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1)." NEJM. 2021;384:989-1002. https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
  2. FDA. Wegovy Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215256s000lbl.pdf
  3. FDA. Zepbound Prescribing Information. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
  4. Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1)." NEJM. 2022;387:205-216. https://www.nejm.org/doi/full/10.1056/NEJMoa2206038
  5. CDC. Adult Obesity Prevalence Maps. https://www.cdc.gov/obesity/adult-obesity-facts/index.html